Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: A combined in vitro and preclinical perspective

Keyphrases

• Lipid Nanoparticles 100%
• Ionizable Lipids 100%
• MRNA Lipid Nanoparticle 100%
• PEGylated Lipids 100%
• MRNA Expression 30%
• PEG-lipid 30%
• Critical Quality Attributes 30%
• SM-102 20%
• Cholesterol 10%
• Production Process 10%
• HEK293 Cells 10%
• In Vitro Study 10%
• Enzymatic Degradation 10%
• High-level Expression 10%
• Particle Size 10%
• Cellular Uptake 10%
• Molar Ratio 10%
• Intramuscular Injection 10%
• Injection Site 10%
• In Vivo Efficacy 10%
• In Vivo Expression 10%
• Formulation Design 10%
• Nanosynthesis 10%
• Cytosolic Release 10%
• Evolving Landscape 10%
• Lipid Nanoparticle Formulations 10%
• In Vivo Mice Study 10%
• DOTAP 10%
• ALC-0315 10%
• DLin-MC3-DMA 10%

Biochemistry, Genetics and Molecular Biology

• Messenger RNA 100%
• Lipid Nanoparticles 100%
• Pegylated Lipid 100%
• Lipid 33%
• In Vitro Study 8%
• Enzymatic Degradation 8%
• Cationic Lipid 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Messenger RNA 100%
• Solid Lipid Nanoparticle 100%
• Polyethylene Glycol 25%
• Intramuscular Injection 8%
• Formulation Design 8%
• 1,2 Dioleoyl 3 Trimethylammoniopropane 8%